Figure 6.

TRPV4 is involved in the VLIUS‐facilitated clearance of β‐amyloid (1‐42). A) Schematic of the experiments. Representative images B) and quantification of β‐amyloid (1‐42) area percentage C) in coronal brain sections at different distances from the bregma reveal a reduction in the β‐amyloid (1‐42) remaining within the brain parenchyma in response to VLIUS compared to the control group. Scale bar: 1 mm. D) Both VLIUS and the TRPV4 agonists (GSK1016790A) promoted β‐amyloid (1‐42) clearance. VLIUS‐promoted clearance was inhibited by co‐administration of a TRPV4 antagonist (GSK2193874). Dots represent individual mice in each group (control group, n = 6; VLIUS group, n = 9; TRPV4 agonist group, n = 8; and TRPV4 antagonist + VLIUS group, n = 7). The results, for which the data are presented as the mean ± SD (error bars denote SD), shown in Figure 6(C) and (D) were analyzed using the Mann‐Whitney U test and ANOVA followed by Tukey's post‐hoc test, respectively, to assess between‐group differences. An asterisk indicates p < 0.05.